Younger DCIS Patients Face Higher Recurrence Risk After Breast-Conserving Surgery

Article

Following breast-conserving surgery for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas.

Following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas, reported Kimberly Van Zee, MD, FACS, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, at the 33rd Annual Miami Breast Cancer Conference, held March 10–13 in Miami Beach, Florida.

“Young age (younger than age 40 years at diagnosis) is a highly significant risk factor for any recurrence after BCS for DCIS,” Dr. Van Zee said, during her review of the available research.

Ten-year recurrence rates of 27.3% for women younger than 40 vs 7.5% among women 80 or older,” she said. “This age effect persists even after adjusting for other factors that vary by age.”

“Older age was associated with lower recurrence in both cohorts that did and did not receive radiation,” she added.

Women younger than 40 years face a seven-fold higher risk of invasive recurrence than do women age 80 or older at the time of DCIS diagnosis.

“In women younger than 40 years, invasive recurrences are more likely than DCIS recurrences,” she noted, whereas DCIS recurrences are more common in women age 40 or older.

“Age is an important factor that should be considered in weighing the various treatment options, including surgical options and the use of adjuvant radiation and endocrine therapies,” Dr. Van Zee said. “Women age 80 or older are at low risk of recurrence, even in the absence of adjuvant therapies.”

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content